FDA 483 - Fresenius Kabi USA, LLC - June 13, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Fresenius Kabi USA, LLC in Wilson, NC, a sterile drug manufacturer, revealed six observations concerning significant deficiencies in aseptic processing controls. Issues included inadequate procedures to prevent microbiological contamination, insufficient validation of aseptic processes, and failures in production and laboratory controls. Additionally, the firm's batch records were deficient, and there was a failure to thoroughly review unexplained discrepancies.
ID · eb0b4e2c-4c39-4ffb-a765-2f01adf7efef